DRREDDYNSEDr. Reddy's Laboratories Limited· PharmaceuticalsMediumNeutral
Announced Tue, 12 May · 17:07 IST

Dr. Reddy's Laboratories Limited has informed the Exchange regarding Change in Director(s) of the company.

Management Changes View source PDF

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+2.7%1-day move
₹1267.50
prior close
₹1245.60
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.0+1.5+1.7+2.1+2.7+6.0+5.0+5.2+4.2+3.4+0.1+0.9-2.4
Up moveDown movePending
AI summary

Dr. Reddy's Laboratories' Board of Directors approved several key appointments at its May 12, 2026 meeting. The Board re-appointed Dr. K P Krishnan as Independent Director for a second 5-year term (January 2027 to January 2032) and appointed Mr. Srikanth Velamakanni (Co-Founder and CEO of Fractal, an AI company) as a new Independent Director for 5 years (July 2026 to June 2031). Additionally, the company appointed Deloitte Haskins & Sells, LLP as its new Statutory Auditors for a 5-year term, replacing the previous auditors. M/s Sagar & Associates was re-appointed as Cost Auditors for FY 2026-27. Mr. Sandeep Khandelwal, who heads the India subcontinent business (a USD 750 million operation), was elevated to Senior Management Personnel and inducted into the Management Council.

Likely market impact

The appointment of Deloitte as statutory auditors represents a change in audit firm, which investors should monitor for any implications. The addition of two experienced Independent Directors, including a prominent AI technology leader, could bring fresh expertise to the board. Sandeep Khandelwal's elevation strengthens the senior leadership team ahead of potential succession planning.